Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer
Journal of Clinical Medicine · 11.01.2023 · 12 (2) · 603
DOI: 10.3390/jcm12020603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.01.2023. Verfasst von Chun-Ting Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung 40705, Taiwan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic marker in endometrial cancer (EC). However, the role of TILs in EC with distinct histology grades and molecular types (such as mismatch repair [MMR] deficiency) has not yet been made clear. We retrospectively included 237 patients with primary EC who underwent a standard staging operation of laparoscopic or laparotomy total hysterectomy and bilateral salpingo-oophorectomy for analyses. An independent pathologist who was blind to the study patients’ information reviewed the pathologic slides to assess TILs according to the method introduced by the International Immuno-Oncology Biomarkers Working Group in 2017. The outcomes of interest included both progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method was used to determine the curves of PFS and OS according to TILs, and also in the relevant subgroups (low-grade vs. high-grade, MMR-proficient vs. MMR-deficient). After a median follow-up duration of 1.82 years, 18 patients had experienced either disease progression or death. Overall, TILs (+) were not associated with PFS or OS. We did observe, however, that TILs (+) were associated with a better PFS (p = 0.045) in patients with high-grade EC, but not in those with low-grade tumors (p = 0.733). The effect of TILs on PFS was not observed in patients with MMR-proficient (p = 0.347) or MMR-deficient (p = 0.168) EC. TILs were associated with a better PFS in patients with high-grade EC. Our results suggest that TILs may be a potential prognostic marker in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
- Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan.
- Institute of Biomedical Sciences and Rong-Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung 40227, Taiwan.
ORCID-Profile: Lou Sun, Ming-Jer Chen, Jun-Sing Wang, Chien-Hsing Lu
Zitieren
APA
Fan, C. T., Hsu, S. T., Sun, L., Hwang, S. F., Liu, C. K., Shih, Y. H., Chen, M. J., Li, H. N., Wang, J. S., Wen, M. C., & Lu, C. H. (2023). Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. Journal of Clinical Medicine, 12(2), 603. https://doi.org/10.3390/jcm12020603
Vancouver
Fan CT, Hsu ST, Sun L, Hwang SF, Liu CK, Shih YH, et al. Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. Journal of Clinical Medicine. 2023;12(2):603. doi:10.3390/jcm12020603
BibTeX
@article{Fan2023,
author = {Fan, Chun-Ting and Hsu, Shih-Tien and Sun, Lou and Hwang, Sheau-Feng and Liu, Chih-Ku and Shih, Yu-Hsiang and Chen, Ming-Jer and Li, Hsin-Ni and Wang, Jun-Sing and Wen, Mei-Chin and Lu, Chien-Hsing},
title = {Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {2},
pages = {603},
doi = {10.3390/jcm12020603}
}
EUVIMED